Cargando...
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T...
Guardado en:
| Publicado en: | Ann Oncol |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516045/ https://ncbi.nlm.nih.gov/pubmed/25712455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv110 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|